<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Onconetix Inc — News on 6ix</title>
    <link>https://6ix.com/company/onconetix-inc</link>
    <description>Latest news and press releases for Onconetix Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 09 Apr 2026 12:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/onconetix-inc" rel="self" type="application/rss+xml" />
    <item>
      <title>Onconetix Highlights Realbotix&apos;s Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-highlights-realbotixs-launch-of-vinci-ai-vision-system-with-delivery-of-first-vinci-equipped-humanoid-robot-to-ericsson-2</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-highlights-realbotixs-launch-of-vinci-ai-vision-system-with-delivery-of-first-vinci-equipped-humanoid-robot-to-ericsson-2</guid>
      <pubDate>Thu, 09 Apr 2026 12:30:00 GMT</pubDate>
      <description>Vinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, April 09, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix’s previously announced pending a</description>
    </item>
    <item>
      <title>Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy</title>
      <link>https://6ix.com/company/onconetix-inc/news/onco-innovations-executes-engagement-agreement-with-rdi-partners-and-establishes-onco-innovations-au-pty-ltd-to-advance-australian-phase-i-strategy</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onco-innovations-executes-engagement-agreement-with-rdi-partners-and-establishes-onco-innovations-au-pty-ltd-to-advance-australian-phase-i-strategy</guid>
      <pubDate>Tue, 07 Apr 2026 22:00:00 GMT</pubDate>
      <description>Company also announces Marketing Engagement VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / Onco-Innovations Limited (CBOECA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ) (&quot;Onco&quot; or the &quot;Company&quot;) is pleased to announce the execution of an engagement ...</description>
    </item>
    <item>
      <title>Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-highlights-realbotix-ai-humanoid-robot-delivery-update-46</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-highlights-realbotix-ai-humanoid-robot-delivery-update-46</guid>
      <pubDate>Thu, 02 Apr 2026 12:30:00 GMT</pubDate>
      <description>Realbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a subsidiary of Realbotix Corp. CINCINNATI, Ohio, April 02, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix’s previously</description>
    </item>
    <item>
      <title>Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-appoints-david-white-as-chief-executive-officer-and-sammy-dorf-as-member-of-the-board-of-directors-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-appoints-david-white-as-chief-executive-officer-and-sammy-dorf-as-member-of-the-board-of-directors-1</guid>
      <pubDate>Tue, 31 Mar 2026 12:30:00 GMT</pubDate>
      <description>Experienced Leadership Team Positioned to Execute Pending Transformative Acquisition of Realbotix LLC and Drive Long-Term Shareholder Value CINCINNATI, Ohio, March 31, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced the appointment of David White as Chief Executive Officer, effective March 18, 2026, and the appointment of Sammy Dorf as a member of the Company’s Board of Directors and the Audit Committee, effective March 19, 2026. Karina Feda</description>
    </item>
    <item>
      <title>Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-highlights-realbotixs-role-in-ericssons-world-first-6g-trial-demonstration-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-highlights-realbotixs-role-in-ericssons-world-first-6g-trial-demonstration-1</guid>
      <pubDate>Wed, 25 Mar 2026 16:47:00 GMT</pubDate>
      <description>Realbotix Humanoid Robot — Ericsson’s First Enterprise Robotics Client — Featured as Live Connected Endpoint in Pre-Standard 6G Over-the-Air Trial at Ericsson’s U.S. Headquarters; Onconetix Has Entered into a Definitive Agreement to Acquire Realbotix CINCINNATI, Ohio, March 25, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) wishes to draw its shareholders’ attention to a development reported by Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) (</description>
    </item>
    <item>
      <title>Onconetix, Inc. Announces 1-for-5 Reverse Stock Split</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-inc-announces-1-for-5-reverse-stock-split-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-inc-announces-1-for-5-reverse-stock-split-1</guid>
      <pubDate>Mon, 23 Mar 2026 12:30:00 GMT</pubDate>
      <description>CINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology, today announced that its Board of Directors (the “Board of Directors” or “Board”) has approved a 1-for-5 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on March 25, 2</description>
    </item>
    <item>
      <title>Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-acquire-realbotix-llc-usa-130000541</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-acquire-realbotix-llc-usa-130000541</guid>
      <pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
      <description>A leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech Inc), and Realbotix LLC. (“Realbotix”), a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT) (“Realbotix Parent “), today announced the signing of a definitive share exchange agreement pursuant to which Onconetix</description>
    </item>
    <item>
      <title>Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-announces-financing-12-9-123000740</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-announces-financing-12-9-123000740</guid>
      <pubDate>Fri, 26 Sep 2025 12:30:00 GMT</pubDate>
      <description>CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (&quot;Onconetix&quot; or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology, announced the September 22, 2025 signing and closing of a private placement of (i) shares of the Company&apos;s Series D Convertible Preferred Stock, $0.00001 par value (the &quot;Series D Preferred Stock&quot;), and (ii) warrants (the &quot;Warrants&quot;)</description>
    </item>
    <item>
      <title>Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement</title>
      <link>https://6ix.com/company/onconetix-inc/news/joint-press-release-onconetix-ocuvex-121500161</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/joint-press-release-onconetix-ocuvex-121500161</guid>
      <pubDate>Fri, 26 Sep 2025 12:15:00 GMT</pubDate>
      <description>CINCINNATI, OH &amp; FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men&apos;s health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025. After careful consideration and constructive dialogue, both companies have jointly determined that pursuing indep</description>
    </item>
    <item>
      <title>Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-announces-subsidiary-proteomedix-licenses-120000727</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-announces-subsidiary-proteomedix-licenses-120000727</guid>
      <pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
      <description>CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (&quot;Onconetix&quot; or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG (“Proteomedix”) has signed a licensing agreement, with Immunovia AB, a pancreatic cancer diagnostics company based in Lund, Sweden. Under the terms of the agreement, Prote</description>
    </item>
    <item>
      <title>Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-ocuvex-therapeutics-announce-execution-121700966</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-ocuvex-therapeutics-announce-execution-121700966</guid>
      <pubDate>Wed, 16 Jul 2025 12:17:00 GMT</pubDate>
      <description>CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates, today announced that they have entered into a definitive merger agreement (the “Merger Agreement”). Andrew J. Oakley, Chairman of the Board of Onconetix, stated, “We continue to believe that the proposed transaction with</description>
    </item>
    <item>
      <title>Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-inc-announces-positive-decision-122200849</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-inc-announces-positive-decision-122200849</guid>
      <pubDate>Mon, 16 Jun 2025 12:22:00 GMT</pubDate>
      <description>CINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology, today reported that on June 11, 2025, the Company received a decision from the Nasdaq Hearings Panel granting the Company’s request for continued listing on The Nasdaq Stock Market, subject to the Company demonstrating compliance</description>
    </item>
    <item>
      <title>Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-inc-announces-1-85-153000206</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-inc-announces-1-85-153000206</guid>
      <pubDate>Wed, 11 Jun 2025 15:30:00 GMT</pubDate>
      <description>CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology, today announced that the Company’s stockholders have approved a proposal to effect a reverse split, which was voted on at the Company’s 2025 special meeting of stockholders (the “Special Meeting”) held on May 30, 2025, and that i</description>
    </item>
    <item>
      <title>Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-inc-announces-receipt-additional-205000196</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-inc-announces-receipt-additional-205000196</guid>
      <pubDate>Thu, 22 May 2025 20:50:00 GMT</pubDate>
      <description>Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May 20, 2025 indicating that the Company’s failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the “10-Q”) is in violation of Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”). This announcement is made in compliance with Nasd</description>
    </item>
    <item>
      <title>Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-signs-letter-intent-potential-123000397</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-signs-letter-intent-potential-123000397</guid>
      <pubDate>Tue, 08 Apr 2025 12:30:00 GMT</pubDate>
      <description>CINCINNATI, April 08, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced that they have signed a Non-Binding Letter of Intent contemplating a potential business combinatio</description>
    </item>
    <item>
      <title>Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-announces-successful-clinical-validation-124500428</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-announces-successful-clinical-validation-124500428</guid>
      <pubDate>Mon, 24 Mar 2025 12:45:00 GMT</pubDate>
      <description>CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (&quot;Onconetix&quot; or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced that new clinical data of Proclarix® was presented on March 23, 2025 during the 2025 European Association of Urology (EAU) congress, which data further demonstrates the strong clinical performance of Proc</description>
    </item>
    <item>
      <title>Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetix-announces-clinical-data-innovative-120000679</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetix-announces-clinical-data-innovative-120000679</guid>
      <pubDate>Wed, 19 Mar 2025 12:00:00 GMT</pubDate>
      <description>CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced that an abstract has been accepted for presentation at the 2025 European Association of Urology (EAU) congress taking place March 21-24, 2025, in Madrid, Spain. The presentation, titled, “Clinical Perform</description>
    </item>
    <item>
      <title>Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders</title>
      <link>https://6ix.com/company/onconetix-inc/news/onconetixtm-chief-executive-officer-dr-neil-j-campbell-issues-letter-to-shareholders</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/onconetixtm-chief-executive-officer-dr-neil-j-campbell-issues-letter-to-shareholders</guid>
      <pubDate>Tue, 19 Dec 2023 05:00:00 GMT</pubDate>
      <description>CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) (&quot;Onconetix&quot; or the “Company”) today issued the following shareholder letter from</description>
    </item>
    <item>
      <title>Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™</title>
      <link>https://6ix.com/company/onconetix-inc/news/blue-water-biotech-acquires-proteomedix-as-part-of-transformation-to-commercial-stage-oncology-company-announces-name-change-to-onconetixtm</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/blue-water-biotech-acquires-proteomedix-as-part-of-transformation-to-commercial-stage-oncology-company-announces-name-change-to-onconetixtm</guid>
      <pubDate>Mon, 18 Dec 2023 05:00:00 GMT</pubDate>
      <description>Transaction strengthens commercial business with addition of diagnostics product and initial focus on prostate cancer CINCINNATI, Dec. 18, 2023 (GLOBE</description>
    </item>
    <item>
      <title>Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company</title>
      <link>https://6ix.com/company/onconetix-inc/news/blue-water-biotech-signs-non-binding-term-sheet-to-acquire-a-commercial-stage-oncology-company</link>
      <guid isPermaLink="true">https://6ix.com/company/onconetix-inc/news/blue-water-biotech-signs-non-binding-term-sheet-to-acquire-a-commercial-stage-oncology-company</guid>
      <pubDate>Thu, 02 Nov 2023 04:00:00 GMT</pubDate>
      <description>Transaction will Advance Company’s Shift in Business Strategy Aligned with Life Sciences Industry Expertise of New Leadership Team CINCINNATI, Nov. 02, 2023</description>
    </item>
  </channel>
</rss>